EGFR and lung adenocarcinoma: This, in addition to the fact that EGFR mutations are the most common druggable genetic alterations in lung adenocarcinomas (10–16% in Caucasians, up to 78% in Asians [7, 8, 10]), and the fact that our series does not include patients treated with the third generation TKI Osimertinib, confirm that anti-EGFR treatments represent the cornerstone of modern targeted therapies in this setting.